ResistanceBio (Viosera Therapeutics)
ResistanceBio set out to design drugs that stop cancers becoming resistant to treatment. The company is no longer active.
Overview
ResistanceBio, incorporated as Viosera Therapeutics, aimed to solve acquired drug resistance in cancer by modelling how tumours evolve under therapy and designing compounds against the resistance routes. It grew to about 15 people with sites in San Francisco and the St. Louis area before the YC directory marked it inactive. Recorded here as wound down; no acquirer or successor is named because none was found in a primary source.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanySerinus Biosciences
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyBlank Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAlgen Biotechnologies
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyArpeggio Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.